WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012093255) USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/093255    International Application No.:    PCT/GB2012/050002
Publication Date: 12.07.2012 International Filing Date: 03.01.2012
IPC:
A61K 31/05 (2006.01), A61K 31/19 (2006.01), A61K 31/4015 (2006.01), A61P 25/08 (2006.01)
Applicants: GW PHARMA LIMITED [GB/GB]; Porton Down Science Park Salisbury Wiltshire SP4 0JQ (GB) (For All Designated States Except US).
OTSUKA PHARMACEUTICAL CO. LIMITED [JP/JP]; 9, Kanda-Tsukasamachi 2-chome, Chiyoda-ku Tokyo, 101-8535 (JP) (For All Designated States Except US).
WHALLEY, Benjamin [GB/GB]; (GB) (For US Only).
WILLIAMS, Claire [GB/GB]; (GB) (For US Only).
STEPHENS, Gary [GB/GB]; (GB) (For US Only)
Inventors: WHALLEY, Benjamin; (GB).
WILLIAMS, Claire; (GB).
STEPHENS, Gary; (GB)
Agent: HARRISON GODDARD FOOTE; 4th Floor, Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG (GB)
Priority Data:
1100043.7 04.01.2011 GB
Title (EN) USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY
(FR) UTILISATION DU CANNABIDIOL (CBD) PHYTOCANNABINOÏDE EN COMBINAISON AVEC UN ANTIÉPILEPTIQUE STANDARD (SAED) DANS LE TRAITEMENT DE L'ÉPILEPSIE
Abstract: front page image
(EN)The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels,for use in the treatment of epilepsy.The SAED is preferably one which • modifies low-threshold or transient neuronal calcium currents,or • reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.
(FR)L'invention concerne l'utilisation de cannabidiol (CBD) à une dose supérieure à 300mg/jour, en combinaison avec un antiépileptique standard (SAED) qui agit par l'intermédiaire des canaux sodiques ou calciques, dans le traitement de l'épilepsie. De préférence, le SAED • modifie les courants calciques neuronaux à seuil bas ou transitoires ou • réduit les décharges neuronales à haute fréquence et les potentiels d'action dépendant du sodium, et renforce les effets du GABA. Les SAED préférés sont l'éthosuximide et le valproate.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)